A Phase 1 interventional study of gel Interferon arm and gel Interferon and interferon suppository arm in Cervical Dysplasia and HPV Infection, sponsored by Mongolian National University of Medical Sciences. Completed at 1 site in Mongolia. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Mongolian National University of Medical Sciences · Phase 1, Interventional, and Treatment
Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. During the years pap smear analysis of implemented in all rural areas and clinicians, lab technicians have been taught for the cervical cancer screening. However, the project has finished in 2015 and the rural and district hospitals has lost the trained professionals. Still the cervical cancer is in second place after liver cancer in women.
The purpose of the study is to identify the type of HPV genotype and to treat the HPV infection by local interferon α2b.
Materials and methods: HPV positive patients will be enrolled to the study. HPV genotype will be determined by the PCR in laboratory. Pap smear will be taken and staged by the CIN. Pathological tissue will be taken under colposcopy with acetic acid test. Follow up visit will be done on 10th, 30th days of the treatment.
At the end of 90th days of treatment, pap and histology test will be repeated and CIN regression or viral eradication will be evaluated.
The purpose of the study is to evaluate the efficacy of interferon treatment for HPV infection shedding and early CIN change.
Women aging from 20-40 years will be enrolled in the study. The treatment will be held in two arms. One arm will be administered only vaginal gel interferon treatment. The other arm will receive both vaginal gel interferon and rectal suppositories with interferon dosing 3,000,000 IU.
In the beginning of the study all patient will have cervical pap smear and HPV typing.
HPV testing will be done using real time PCR method to determine the subtype of HPV (16,18,31,33,35,39,45,51,52,56,59,68).
At the beginning and at the end of the study all patient will have histology test.
Histology test will be done Giemsa staining and evaluated by WHO 2014 classification of cervical histology including CINI, CINII, CINIII, cervical cancer in situ and further.
Pap smear will be evaluated by Bethesda classification. Immunohistology staining will be done on the cervical tissue using anti-CD3 and anti-CD19 to evaluate the B cell invasion into the cervix.
409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
This study's enrollment of 60 is below the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Browse Uterine Cervical Dysplasia studies →Mongolian National University of Medical Sciences is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Interferon α2b gel treatment for 30 days.
Drug: gel Interferon arm
Interferon α2b gel treatment for 30 days + Interferon α2b 3 MIU rectal suppository for 10 days
Drug: gel Interferon arm · Drug: gel Interferon and interferon suppository arm
0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
Also known as: Interferon alfa-2b low dose local treatment
0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days. 3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy.
Also known as: Interferon alfa-2b low dose local and high dose systemic treatment
Pap smear
LSIL, HSIL or regression of the change will be assessed.
Time frame: 90 days
Colposcopic change
Cervical changes before and after treatment will be compared.
Time frame: 90 days
Histopathologic change
CINI, CINII or regression of the cervical dysplasia will be evaluated.
Time frame: 90 days
Immunohistochemical change
Anti CD-3 and anti CD-19 staining will be done and stained cells will be calculated and compared.
Time frame: 90 days
Plan to share: No
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mongolian National University of Medical Sciences